LDS/Medical Tests/Epstein-Barr Virus (EBV) Antibody Panel

Epstein-Barr Virus (EBV) Antibody Panel

The Epstein-Barr virus (EBV) is a member of the herpes virus family, and is responsible for many disorders, including infectious mononucleosis, and other lymphoproliferative disorders. EBV was originally recognized during studies of Burkitt lymphoma in Africa and only later associated with mononucleosis. In young adults, EBV infection may be clinically manifested as infectious mononucleosis with typical symptoms of sore throat, fever, and lymphadenopathy. Splenomegaly is quite common in the disease and a serious complication is rupture of the spleen. Following primary EBV infection, the virus establishes its latency in B lymphocytes that may extend through life. Reactivation of EBV infection or enhanced EBV activation has been documented in immunodeficient or immunosuppressed patients, i.e., organ transplant patients, individuals with malignancies, HIV infected patients, pregnant women, and persons of advanced age.

EBV has also been associated in the pathogenesis of two human cancers: Burkitt’s lymphoma and nasopharyngeal carcinoma. Several reports have suggested that EBV infection is associated with “chronic fatigue syndrome.” The laboratory diagnosis of acute EBV is serologic. Most modern EBV serology tests detect antibody to viral capsid antigens (VCA). These are viral structural proteins necessary for its replication. The IgM response to VCA is among the earliest detectable humoral immune responses, usually present at the onset of the disease and peaking within three to six weeks. VCA-IgM levels are transient, declining rapidly and usually becoming undetectable within two to four months from onset of clinical symptoms. VCA-IgG antibodies develop later and persist for life. Early antigen antibodies (anti-EA) develop next, are most often positive at 1 month after presentation, typically last for 2–6 months, and may last up to 10 months in low titers.

Epstein Barr nuclear antigen (anti-EBNA) antibody begins to appear in the third or fourth week from onset of disease but is uniformly present by 6 months and persists indefinitely. Detection of VCA IgM usually confirms acute EBV infection, because this antibody disappears by 3 months after the illness begins. Detection of VCA and EBNA IgG usually indicate current/persistent (if VCA IgM positive) or past infection (IgM negative). IgG to the early antigen D (EA-D) appears in the acute phase and generally falls to undetectable levels after 3 to 6 months. In many people, detection of antibody to the early antigen is a sign of active infection, but in 20-30% of healthy individuals IgG to EA-D remains detectable for life. Reactivation of latent EBV can occur in immunodeficient or immunosuppressed patients. IgM-VCA and EBV-EA antibodies may be transiently positive with rapidly rising high titers of IgG-VCA in reactivation. False positive IgM levels have been reported due to cross-reactivity with cytomegalovirus (CMV), toxoplasma, and herpes simplex antibodies. Rheumatoid factor may also cause false positive IgM results.

  • In diagnosis of EBV infection
  • Diagnosis of infectious mononucleosis
  • As an aid in diagnosis of Burkitt’s lymphoma
  • As an aid in diagnosis of nasopharyngeal carcinoma
  • As an aid in diagnosis of chronic fatigue syndrome
  • Screening for EBV infection in immunocompromised patients for pre-emptive therapy

Increased in:

  • EB virus infection such as infectious mononucleosis
  • Burkitt lymphoma nasopharyngeal carcinoma
  • Chronic fatigue syndrome
  • Immunocompromised patients
EBV VCA-IgG EBV VCA-IgM EBNA-IgG EBV EA-IgG Diagnosis
Negative Negative Negative Negative Not exposed
Negative Positive Negative Negative Early Infection
Positive Positive Negative Negative or Positive Acute / Primary Infection
Positive Positive Positive Negative or Positive Transient Phase or Reactivation
Positive Negative Positive Positive or Negative Past Infection

 

Negative (See each antigen for more)

 

 

Immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA). 

Serum (SST). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7 days
  • Frozen: 60 days
CMV Antibody, Rheumatoid Factor, Toxoplasma Antibody, Mono Spot (Infectious Mononucleosis Screen).
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login